Mar 1, 2026 Log in

News

ScinoPharm Taiwan (1789) Q1 2026 EPS: NT$0.02

Citation-Grade Primary-source linked Schema.org verified NQ 0 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Mar 1, 2026 9:00 AM ・ Updated Jun 13, 2026 8:26 AM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million.
This reflects the latest financial status of the company in the biotechnology and healthcare industry.

ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.

PRIMARY SOURCE PR Times View source Distributor: PR Times
Published: Mar 1, 2026

Company Code: 1789 Company Name: ScinoPharm Taiwan, Ltd. Industry: Biotechnology and Healthcare Industry Period: Q1 2026 Basic Earnings Per Share: NT$0.02 Operating Revenue: NT$660 million After-tax Net Profit: NT$17 million

FACT BOX

Source: PR Times
Category: News

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Mar 1, 2026 9:00 AM — Distributor PR Times
Collected　May 7, 2026 8:00 AM
AI structured & analyzed　May 7, 2026 8:04 AM
Desk-reviewed & published　Mar 1, 2026 9:00 AM

FAQ

What are the key facts in this article?

Where is the primary source?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-1789-2026Q1

When was it published?

Mar 1, 2026

Cite this article — HOW TO CITE

Washin AI News Desk“ScinoPharm Taiwan (1789) Q1 2026 EPS: NT$0.02”AI News by Washin Village（和心村）, Mar 1, 2026. https://aeo.washinmura.jp/ai/%E5%8F%B0%E7%81%A3%E7%A5%9E%E9%9A%86%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/en/news/2026-05-06-scinopharm-taiwan-1789-q1-2026-eps-nt-0

AI CRAWLER ACTIVITY

as of Jul 7, 2026

AI crawler visits to this article (cumulative)Measuring since publication (no visits recorded yet)

Site-wide cumulative

ClaudeBot

bot_visits_summary

4594k

last Jul 7, 2026

GPTBot

bot_visits_summary

3262k

last Jul 7, 2026

Bingbot

bot_visits_summary

2087k

last Jul 7, 2026

Applebot

bot_visits_summary

1648k

last Jul 7, 2026

Google AI

bot_visits_summary

1648k

last Jul 7, 2026

Googlebot

bot_visits_summary

1262k

last Jul 7, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 台灣神隆股份有限公司 Back to newsroom (13)

Copied